REGN241220P955000
- 26.88
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Express News | Regeneron Pharmaceuticals Shares Are Trading Higher After the Company Announced Its QUASAR Trial Investigating EYLEA HD Met Its Primary Endpoint for the Treatment of Patients With Macular Edema
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target
Express News | Bayer AG - Approximately 90% of Aflibercept 8 Mg Patients Were Extended to Every 8-Week Dosing and Maintained Their Interval Through 36 Weeks
Express News | Regeneron Pharmaceuticals Inc - Supplementary Biologics License Application Planned for Q1 2025
Express News | Regeneron Pharmaceuticals Inc - Safety Data Consistent With Known Eylea Hd and Eylea Profiles
Express News | Eylea Hd® (Aflibercept) Injection 8 Mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision With Extended Dosing Intervals in Patients With Macular Edema Following Retinal Vein Occlusion
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Regeneron Pharma Price Target Announced at $165.00/Share by Canaccord Genuity
Regeneron Pharma Initiated at Hold by Canaccord Genuity
Worst Performing Stocks for Tax Loss Selling – Wolfe
Another Week, Another Index Record | Lkive Stock
Palantir, Tesla, and Other Stocks That Have Soared Past Wall Street's Price Targets
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
Weekly Buzz: Tech stocks hit high scores on ominous day
Market Mixed on Friday the 13th | Livestock
Regeneron Down 15.5% Year to Date: How to Play the Stock?
Thursday Ends in Index Declines | Wall Street Today
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock